A phase 2A clinical trial of ALK-001 in geographic atrophy
Ended Project Grant Awarded Last action
- Award ID
- R44EY021988
- Recipient
-
Alkeus Pharmaceuticals Inc. UEI MQZNHQ1FW6M3
- Awarding agency
-
National Eye Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,086,555
Award facts
- Assistance listing
- 93.867 Vision Research
- Completion date
- Originally
- Place of performance
- West Somerville, MA 02144, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,032,268 | |
| Original award | $1,054,287 |
Quick answers
Who received award R44EY021988?
R44EY021988 was awarded to Alkeus Pharmaceuticals Inc. by National Eye Institute (National Institutes of Health) on September 1, 2012.
How much is award R44EY021988 worth?
$2,086,555 has been obligated on R44EY021988.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award